Study results from a phase 2 trial in subjects with progressive supranuclear palsy (PSP) led by Transposon Therapeutics report a reduction in NfL, IL-6, and osteopontin after treatment with TPN-101, as well as stabilization of symptoms (NCT04993768); the FDA has granted Fast Track designation for TPN-101 for PSP based on study results. The gene discussed is IL6; the disease is progressive supranuclear palsy.